$HCWB
HCW Biologics Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127198 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $426.4K
YoY Change -50.02%
Cost Of Revenue $341.1K
YoY Change -49.71%
Gross Profit $85.29K
YoY Change -51.2%
Gross Profit Margin 20.0%
Selling, General & Admin $2.545M
YoY Change -27.74%
% of Gross Profit 2984.28%
Research & Development $1.187M
YoY Change -28.82%
% of Gross Profit 1391.7%
Depreciation & Amortization $128.5K
YoY Change -54.23%
% of Gross Profit 150.61%
Operating Expenses $3.776M
YoY Change -28.12%
Operating Profit -$3.690M
YoY Change -27.33%
Interest Expense $223.4K
YoY Change 133.85%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$3.902M
YoY Change -20.98%
Income Tax
% Of Pretax Income
Net Earnings -$3.902M
YoY Change -20.98%
Net Earnings / Revenue -915.12%
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$0.10
COMMON SHARES
Basic Shares Outstanding 37.82M 37.82M
Diluted Shares Outstanding 37.82M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $998.2K
YoY Change -91.1%
Cash & Equivalents $1.000M
Short-Term Investments
Other Short-Term Assets $88.13K
YoY Change -49.61%
Inventory
Prepaid Expenses $356.2K
Receivables $651.8K
Other Receivables $0.00
Total Short-Term Assets $2.094M
YoY Change -84.88%
LONG-TERM ASSETS
Property, Plant & Equipment $22.83M
YoY Change 54.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.600M
YoY Change 0.0%
Other Assets $28.48K
YoY Change -79.31%
Total Long-Term Assets $24.46M
YoY Change 12.38%
TOTAL ASSETS
Total Short-Term Assets $2.094M
Total Long-Term Assets $24.46M
Total Assets $26.56M
YoY Change -25.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.67M
YoY Change 618.68%
Accrued Expenses $1.057M
YoY Change -53.3%
Deferred Revenue
YoY Change
Short-Term Debt $6.341M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.06M
YoY Change 455.01%
LONG-TERM LIABILITIES
Long-Term Debt $6.463M
YoY Change 2.05%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $6.463M
YoY Change 2.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.06M
Total Long-Term Liabilities $6.463M
Total Liabilities $36.53M
YoY Change 210.88%
SHAREHOLDERS EQUITY
Retained Earnings -$97.18M
YoY Change 62.37%
Common Stock $3.782K
YoY Change 5.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.970M
YoY Change
Total Liabilities & Shareholders Equity $26.56M
YoY Change -25.44%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.902M
YoY Change -20.98%
Depreciation, Depletion And Amortization $128.5K
YoY Change -54.23%
Cash From Operating Activities -$2.926M
YoY Change -47.64%
INVESTING ACTIVITIES
Capital Expenditures $37.07K
YoY Change -94.09%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$37.07K
YoY Change -100.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.800M
YoY Change -30277.16%
NET CHANGE
Cash From Operating Activities -2.926M
Cash From Investing Activities -37.07K
Cash From Financing Activities 2.800M
Net Change In Cash -163.1K
YoY Change -104.32%
FREE CASH FLOW
Cash From Operating Activities -$2.926M
Capital Expenditures $37.07K
Free Cash Flow -$2.964M
YoY Change -52.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Gross Profit
GrossProfit
880442
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1667442
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1186913
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5539919
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5339383
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1509936
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1639152
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5106674
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4799437
CY2023Q3 us-gaap Legal Fees
LegalFees
2075279
CY2024Q3 us-gaap Legal Fees
LegalFees
949455
us-gaap Legal Fees
LegalFees
4610091
us-gaap Legal Fees
LegalFees
15761531
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1300000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5252657
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3775520
us-gaap Operating Expenses
OperatingExpenses
15256684
us-gaap Operating Expenses
OperatingExpenses
27200351
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5077880
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3690235
us-gaap Operating Income Loss
OperatingIncomeLoss
-14948969
us-gaap Operating Income Loss
OperatingIncomeLoss
-26319909
CY2023Q3 us-gaap Interest Expense
InterestExpense
95514
CY2024Q3 us-gaap Interest Expense
InterestExpense
223363
us-gaap Interest Expense
InterestExpense
284465
us-gaap Interest Expense
InterestExpense
383029
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
234753
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
11310
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
919688
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
52397
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4938641
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3902288
us-gaap Net Income Loss
NetIncomeLoss
-14313746
us-gaap Net Income Loss
NetIncomeLoss
-26650541
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35926921
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35926921
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37823394
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37823394
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35907123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35907123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623459
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37623459
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
37428506
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1901
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
259206
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5070686
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32618927
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7712
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
263423
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4304420
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
28585642
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
219848
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4938641
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23866933
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13461717
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2255
CY2024Q1 hcwb Issuance Of Common Stock Upon Equity Subscription
IssuanceOfCommonStockUponEquitySubscription
2500005
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
244685
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7468061
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
8740601
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
239821
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15280191
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6299769
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
232433
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3902288
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-9969624
us-gaap Net Income Loss
NetIncomeLoss
-14313746
us-gaap Net Income Loss
NetIncomeLoss
-26650541
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
860634
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
501882
us-gaap Share Based Compensation
ShareBasedCompensation
742477
us-gaap Share Based Compensation
ShareBasedCompensation
716940
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
248445
dei Entity Central Index Key
EntityCentralIndexKey
0001828673
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40591
dei Entity Registrant Name
EntityRegistrantName
HCW Biologics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5024477
dei Entity Address Address Line1
EntityAddressAddressLine1
2929 N
dei Entity Address Address Line2
EntityAddressAddressLine2
Commerce Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Miramar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33025
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
842–2024
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
HCWB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37823394
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3595101
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
998221
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1535757
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
651840
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1042413
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
356156
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
230916
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
88131
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6404187
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2094348
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
1599751
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
1599751
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20453184
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22833904
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56538
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
28476
CY2023Q4 us-gaap Assets
Assets
28513660
CY2024Q3 us-gaap Assets
Assets
26556479
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6167223
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
22666107
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2580402
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1056716
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
6340511
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8747625
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30063334
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
6304318
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
6462769
CY2023Q4 us-gaap Liabilities
Liabilities
15051943
CY2024Q3 us-gaap Liabilities
Liabilities
36526103
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36025104
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37823394
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3603
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3782
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83990437
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87209457
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70532323
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97182863
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13461717
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-9969624
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28513660
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26556479
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
853102
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
426423
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1517792
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2171988
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
678325
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
341138
us-gaap Cost Of Revenue
CostOfRevenue
1210077
us-gaap Cost Of Revenue
CostOfRevenue
1291546
CY2023Q3 us-gaap Gross Profit
GrossProfit
174777
CY2024Q3 us-gaap Gross Profit
GrossProfit
85285
us-gaap Gross Profit
GrossProfit
307715
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
15625
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
hcwb Changes In Carrying Amount Of Right Of Use Asset
ChangesInCarryingAmountOfRightOfUseAsset
-1045
hcwb Changes In Carrying Amount Of Right Of Use Asset
ChangesInCarryingAmountOfRightOfUseAsset
-418
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
292383
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-883917
hcwb Change In Deposit For Interest Reserve
ChangeInDepositForInterestReserve
5250000
hcwb Change In Deposit For Interest Reserve
ChangeInDepositForInterestReserve
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
251008
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-829043
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
392802
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12383171
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-242990
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-56541
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18619329
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11392547
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2486950
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
148205
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
10000000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7513050
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-148205
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9697
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2502260
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6530000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-8981
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-88388
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
716
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8943872
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11105563
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2596880
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22326356
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3595101
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11220793
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
998221
us-gaap Interest Paid Net
InterestPaidNet
284465
us-gaap Interest Paid Net
InterestPaidNet
340988
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2095724
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1910698
hcwb Accrued Fixed Asset And Other Liablities
AccruedFixedAssetAndOtherLiablities
0
hcwb Accrued Fixed Asset And Other Liablities
AccruedFixedAssetAndOtherLiablities
829207
hcwb Cumulative Losses To Conduct Product Research And Development In Future
CumulativeLossesToConductProductResearchAndDevelopmentInFuture
94500000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1000000
CY2024Q3 hcwb Legal Fees Incurred But Not Yet Paid
LegalFeesIncurredButNotYetPaid
14400000
CY2024Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
35000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reclassification of Prior Period Presentation of Legal Expenses</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior period amounts have been reclassified to distinguish between General and administrative expenses in the ordinary course of business and legal expenses incurred in connection with the arbitration and Settlement Agreement described in Notes 1. Reclassification of legal expenses incurred in connection with legal proceedings impacts the consolidated interim statements of operations. There is no effect on reporting results of operations from prior periods.</span>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management must apply significant judgment in this process. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from estimates.</span></p>
hcwb Investment Impairment Charges
InvestmentImpairmentCharges
0
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2600000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1200000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4938641
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3902288
us-gaap Net Income Loss
NetIncomeLoss
-14313746
us-gaap Net Income Loss
NetIncomeLoss
-26650541
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35926921
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35926921
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37823394
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37823394
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35907123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35907123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37623459
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37623459
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1869492
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1788137
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1626129
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83814
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y
CY2022Q1 us-gaap Area Of Land
AreaOfLand
12250
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2024Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P1Y
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-02-28
us-gaap Short Term Lease Cost
ShortTermLeaseCost
114510
CY2023Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
42400
CY2024Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
49500
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
127200
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
146400
CY2023 hcwb Commitment Fund
CommitmentFund
4400000
hcwb Commitment Fund
CommitmentFund
2500000
CY2024Q1 hcwb Deposit Account For Interest Reserve
DepositAccountForInterestReserve
5300000
CY2023Q4 hcwb Deposit Account For Credit Loss Reserve
DepositAccountForCreditLossReserve
5300000
CY2024Q3 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
1300000
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
1300000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 hcwb Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 hcwb Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-127198-index-headers.html Edgar Link pending
0000950170-24-127198-index.html Edgar Link pending
0000950170-24-127198.txt Edgar Link pending
0000950170-24-127198-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hcwb-20240930.htm Edgar Link pending
hcwb-20240930.xsd Edgar Link pending
hcwb-ex10_5.htm Edgar Link pending
hcwb-ex10_6.htm Edgar Link pending
hcwb-ex31_1.htm Edgar Link pending
hcwb-ex31_2.htm Edgar Link pending
hcwb-ex32_1.htm Edgar Link pending
hcwb-ex32_2.htm Edgar Link pending
img176362979_0.jpg Edgar Link pending
img176362979_1.jpg Edgar Link pending
img176362979_2.jpg Edgar Link pending
img176362979_3.jpg Edgar Link pending
img176362979_4.jpg Edgar Link pending
img176362979_5.jpg Edgar Link pending
img176362979_6.jpg Edgar Link pending
img176362979_7.jpg Edgar Link pending
img176362979_8.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
hcwb-20240930_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending